Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04452123
Other study ID # GPKENDO2001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2020
Est. completion date December 31, 2023

Study information

Verified date June 2020
Source Charles University, Czech Republic
Contact Jan Humplik, MD
Phone 420377105254
Email humplikj@fnplzen.cz
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ovarian endometriosis (endometrioma) can be a cause of subfertility. According to European Society of Human Reproduction and Embryology (ESHRE) guidelines, surgery for endometrioma is recommended when an endometrioma is more than 3 cm in diameter because this management is associated with better spontaneous conception rates. Nevertheless, surgery can also be potentially associated with a risk of destruction of functional ovarian tissue and reduction in ovarian reserve.

Anti-müllerian hormone (AMH) is a member of the Transforming Growth Factor beta family and is expressed by the small (<8 mm) pre-antral and early antral follicles. The AMH level reflects the size of the primordial follicle pool, and may be the best biochemical marker of ovarian function across an array of clinical situations Its level in serum is almost stable between 20 and 35 years of the woman´s life, unless using hormonal contraception and / or they suffer with Polycystic ovarian syndrome (PCOS). The level of AMH is also a useful indicator for the prediction chances of success of spontaneous or assisted conceptions. However, there paucity of data regarding changes in serum levels of AMH following surgery for endometrioma.

An alternative way for estimating ovarian reserve is quantifying ovarian mass with using standard 3D transvaginal ultrasound calculation (OVM) and assessment of antral follicular count.

The gold standard of endometrioma surgery is laparoscopic excision with suture or gentle coagulation of the rest of ovary or by the use of laparoscopic treatment with argon plasma energy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

- women with endometrioma 3cm and more in diameter

Exclusion Criteria:

- using hormonal contraception or other hormonal treatment last 6 months

- suffer with polycystic ovarian syndrome

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Laparoscopic argon plasma treatment of endometrioma
Laparoscopic Argon Plasma vaporising the endometriotic cyst lining only until haemosiderin pigment stained tissue is no longer visible
Laparoscopic stripping of endometrioma and suture/coagulation of the rest of ovary
Laparoscopic dissecting of capsule of endometrioma and achieving hemostasis with suture of rest of the ovary or with gentle coagulation.

Locations

Country Name City State
Czechia Departement of gynecology and obstetrics, University hospital in Pilsen Pilsen

Sponsors (1)

Lead Sponsor Collaborator
Charles University, Czech Republic

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary AMH Changing of anti-müllerian hormon assay postop. in µg/L 3 days,3-5 week postop., 3 months postop., 1 year (optional)
Primary Antral follicle count (AFC) Ultrasound count of Antral follicles after the surgery, counted 3-5. day of menstrual cycle 3 months, 1 year
Primary Both ovarian volume Ultrasound volume of both ovaries in cm^3, measured 3-5. day of menstrual cycle 3 months, 1 year
See also
  Status Clinical Trial Phase
Completed NCT01268930 - Comparison of Hemostatic Matrix and Bipolar Coagulation in Surgical Treatment of Endometriomas N/A
Completed NCT05323539 - Comparison of Thyroid Volumes in Patients With and Without Endometrioma N/A
Recruiting NCT04178876 - Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS) N/A
Completed NCT06421857 - Hemostatic Measures During Laparoscopic Cystectomy for Endometrioma N/A
Recruiting NCT04151433 - Conservative Endometrioma Surgery N/A
Completed NCT01942122 - DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis Phase 2/Phase 3
Withdrawn NCT00999479 - Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation N/A
Recruiting NCT03687398 - Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls
Not yet recruiting NCT06377553 - PET/MRI for Evaluation of Endometriosis
Not yet recruiting NCT03788720 - Suture of the Ovary After Enucleation of Ovarian Endometrioma N/A
Completed NCT01982526 - Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients
Recruiting NCT05962775 - Ethanol Sclerotherapy Prior to ART N/A
Completed NCT03484546 - Optimum Menstrual Cycle Time for Endometrioma Excision
Completed NCT01808170 - Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve N/A
Recruiting NCT05637073 - Effect of Management of the Endometrioma on Ovarian Reserve
Completed NCT06219044 - Evaluation of Ovarian Reserve and Recurrence Rate After DWLS Diode Laser OMA Vaporization N/A
Recruiting NCT03620838 - Endometrioma Per se Versus Treatment Related Reduction in Ovarian Reserve (ERROR-2 Trial)
Terminated NCT03571776 - Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial N/A
Enrolling by invitation NCT02472873 - Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas N/A
Completed NCT04941833 - Desogestrel for the Preoperative Treatment of Endometrioma Compared With Placebo Phase 2/Phase 3